ReviewAdvances in therapy2023
Histology-Agnostic Drugs: A Paradigm Shift-A Narrative Review.
Review in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Crossing paths: historical and philosophical perspectives on cancer and diabetes classifications.History and philosophy of the life sciences · 2026Article
- Recent Advances in Radiopharmaceuticals for Cancer Diagnosis and Therapy.Oncology research · 2026Review
- A network model for patient-derived drug response in breast cancer integrating multi-omics datasets.bioRxiv : the preprint server for biology · 2025Article
- Non-Coding RNAs in Diagnostic Pathology of High-Grade Central Osteosarcoma.Diagnostics (Basel, Switzerland) · 2025Review
- Advances in Tissue-Agnostic Targeting in Cancer Therapeutics: Current Approvals, Challenges, and Future Directions.Oncology research · 2025Review
- Targeted Therapy Evolution from Defining a Sub-population to Crossing Multi-indications.Advanced pharmaceutical bulletin · 2024Article
- Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study.Future oncology (London, England) · 2024Article
- Seeing the random forest through the decision trees. Supporting learning health systems from histopathology with machine learning models: Challenges and opportunities.Journal of pathology informatics · 2024Review
- Polo-like kinase 2 targeting as novel strategy to sensitize mutant p53-expressing tumor cells to anticancer treatments.Journal of molecular medicine (Berlin, Germany) · 2024Article
- Histology Agnostic Drug Development: An Updated Review.Cancers · 2024Review
- Review
- Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective.PharmacoEconomics · 2024Article
- Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution.International journal of molecular sciences · 2024Review
- Adagrasib in Advanced Solid Tumors Harboring aJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Simulation study for evaluating an adaptive-randomisation Bayesian hybrid trial design with enrichment.Contemporary clinical trials communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer diagnosis and therapeutics have been traditionally based on pathologic classification at the organ of origin. The availability of an unprecedented amount of clinical and biologic data provides a unique window of opportunity for the development of new drugs. What was once treated as a homogeneous disease with a one-size-fits-all approach was shown to be a rather heterogeneous condition, with multiple targetable mutations that can vary during the course of the disease. Clinical trial designs have had to adapt to the exponential growth of targetable mechanisms and new agents, with ensuing challenges that are closer to those experienced with rare diseases and orphan medicines. To face these problems, precision/enrichment and other novel trial designs have been developed, and the concept of histology-agnostic targeted therapeutic agents has emerged. Patients are selected for a specific agent based on specific genomic or molecular alterations, with the same compound used to potentially treat a multiplicity of cancers, granted that the actionable driver alteration is present. There are currently approved drugs for such indications, but this approach has raised issues on multiple levels. This review aims to address the challenges of this new concept and provide insights into possible solutions and frameworks on how to tackle them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.